HK gastroesophageal reflux disease drug ‘K-Cab’ (tegoprazan,Photo) faces an indiscriminate patent barrage.
In K-Cap, 80 companies recently filed for 247 crystalline patent trials, and this time, a pharmaceutical company appeared that challenges substance patents.
According to the industry, on the 26th, Samcheondang Pharmaceutical filed a claim against HK Innoen for passive confirmation of the scope of patent rights of K-Cab substances (expires on August 25, 2031). On December 24 last year, Samcheondang Pharmaceutical filed a passive trial to confirm the scope of the rights to circumvent K-Cap’s crystalline patent.
If generic companies like Samchundang Pharmaceutical manage to avoid substance patents, early generic release after 2026 will be possible.
Among the two patents protecting K-Cab, the material patent was originally until 2026, but HK InnoN postponed the expiration date to August 25, 2031 by extending its duration. In addition, 80 pharmaceutical companies, including Samcheondang Pharmaceutical, applied for a passive trial to confirm the scope of rights for the crystalline patent which expires in March 2036.
Currently, K-Cab has indications such as gastroesophageal reflux disease ▲ erosive ▲ non-erosive gastroesophageal reflux disease ▲ gastric ulcer ▲ antibiotic combination therapy for the eradication of Helicobacter pylori ▲ maintenance therapy after treatment of erosive gastroesophageal reflux disease . Among them, erosive and non-erosive gastroesophageal reflux disease will be protected until 2026, and the remaining indications will be protected until 2031. What Samcheondang Pharmaceutical raised this time is about three indications , including gastric ulcer.
The industry expects that generic companies that have already applied for a decision type patent trial will request the same trial following Samchundang Pharmaceutical.
